A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 478 participants.
Also called NCT03954834
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 478 participants
- Sponsor
- Registry
-
NCT03954834
-
- Other papers using this trial's data
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, India, Japan, Mexico, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT03954834. Randomized; double masking; primary purpose treatment. Start 2019-06-03 (actual); primary completion 2020-10-05 (actual). Results posted on 2021-10-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
- Acronym
- SURPASS-1
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Tirzepatide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct03954834- Content hash
dd7324ec1dcfc3478e3ac604687befac1fc698ae7ba4e61e7c15f0cfd9c4d024